ARCT News and Press, Arcturus Therapeutics Ltd. From 04/20/22

Disclosing topline data from an ongoing Phase 1/2/3 clinical trial, RNA medicines company, Arcturus Therapeutics (NASDAQ:ARCT) said on Wednesday that its self-amplifying mRNA vaccine ARCT-154 showed 95% overall efficacy in the prevention of severe COVID-19 including related deaths. However, t...

95% Efficacy overall for prevention of severe COVID-19 disease including related deaths 55% Efficacy overall for preventing symptomatic COVID-19 disease Study conducted when Delta and Omicron variants were dominant in Vietnam Incidence of unsolicited adverse ev...

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) traded today at $129.60, eclipsing its 52-week high. So far today approximately 33.7 million shares have been exchanged, as compared to an average 30-day volume of 547,000 shares. Arcturus Therapeutics Holdings Inc. has overhead...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare dise...

COVID-19 vaccine developer Arcturus Therapeutics (ARCT +10.6%) have outperformed rival shot makers on Tuesday after Piper Sandler issued positive remarks on the company’s messenger-RNA-based vaccine booster. Identified as LUNAR-COV19 vaccine candidates, Arcturus has three experimental ...

Gainers: BioNTech (BNTX) +72%. Trip.com Group Limited (TCOM) +25%. StoneCo  (STNE) +21%. OraSure Technologies (OSUR) +6%. Brookline Bancorp (BRKL) +5%. Losers: Arcturus Therapeutics Holdings  (ARCT) -12%. Embark Technology (EMBK) -9%. CymaBay Therapeutics&#x...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare dise...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Arcturus Therapeutics (NASDAQ: ARCT) and Moderna (NASDAQ: MRNA) have more than a couple of things in common. Both companies are biotechs that develop mRNA-based medicines, and both stocks soared over the past two years on optimism about their coronavirus vaccine candidates. ...

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2021 Earnings Conference Call February 28, 2022, 4:30 PM ET Company Participants Joseph Payne – President and Chief Executive Officer Andy Sassine – Chief Financial Officer Deepankar Roy – Senior Director Investor Relations Co...